These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17671985)

  • 41. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
    Addeo R; Caraglia M; Cerbone D; Frega N; Cimmino G; Abbruzzese A; Del Prete S
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):499-505. PubMed ID: 20397915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
    Carrato A; Gómez A; Escudero P; Chaves M; Rivera F; Marcuello E; González E; Grávalos C; Constenla M; Manzano JL; Losa F; Maurel J; Dueñas R; Massuti B; Gallego J; Aparicio J; Antón A; Aranda E
    Clin Transl Oncol; 2013 Sep; 15(9):705-11. PubMed ID: 23359181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
    Van Cutsem E; Siena S; Humblet Y; Canon JL; Maurel J; Bajetta E; Neyns B; Kotasek D; Santoro A; Scheithauer W; Spadafora S; Amado RG; Hogan N; Peeters M
    Ann Oncol; 2008 Jan; 19(1):92-8. PubMed ID: 17785764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
    Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
    Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
    Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
    Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of panitumumab in combination chemotherapy clinical trials.
    Weeraratne D; Chen A; Pennucci JJ; Wu CY; Zhang K; Wright J; Pérez-Ruixo JJ; Yang BB; Kaliyaperumal A; Gupta S; Swanson SJ; Chirmule N; Starcevic M
    BMC Clin Pharmacol; 2011 Nov; 11():17. PubMed ID: 22070868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
    Dotan E; Cohen SJ; Starodub AN; Lieu CH; Messersmith WA; Simpson PS; Guarino MJ; Marshall JL; Goldberg RM; Hecht JR; Wegener WA; Sharkey RM; Govindan SV; Goldenberg DM; Berlin JD
    J Clin Oncol; 2017 Oct; 35(29):3338-3346. PubMed ID: 28817371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Panitumumab safety for treating colorectal cancer.
    Stremitzer S; Sebio A; Stintzing S; Lenz HJ
    Expert Opin Drug Saf; 2014 Jun; 13(6):843-51. PubMed ID: 24766434
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
    Weiner LM; Belldegrun AS; Crawford J; Tolcher AW; Lockbaum P; Arends RH; Navale L; Amado RG; Schwab G; Figlin RA
    Clin Cancer Res; 2008 Jan; 14(2):502-8. PubMed ID: 18223225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
    Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
    Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
    Middleton G; Brown S; Lowe C; Maughan T; Gwyther S; Oliver A; Richman S; Blake D; Napp V; Marshall H; Wadsley J; Maisey N; Chau I; Hill M; Gollins S; Myint S; Slater S; Wagstaff J; Bridgewater J; Seymour M
    Eur J Cancer; 2013 Nov; 49(16):3507-16. PubMed ID: 23953030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
    Tzovaras AA; Karagiannis A; Margari C; Barla G; Ardavanis A
    Anticancer Res; 2011 Mar; 31(3):1033-7. PubMed ID: 21498734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
    J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.